You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePalbociclib
Accession NumberDB09073
TypeSmall Molecule
GroupsApproved
DescriptionPalbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.
Structure
Thumb
Synonyms
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
External Identifiers
  • PD 0332991
  • PD 332991
  • PD-0332991
  • PD-332991
  • PD0332991
  • PD332991
  • UNII-G9ZF61LE7G
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ibrancecapsule75 mg/1oralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
Ibrancecapsule75 mgoralPfizer Canada Inc2016-04-20Not applicableCanada
Ibrancecapsule100 mg/1oralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
Ibrancecapsule100 mgoralPfizer Canada Inc2016-04-19Not applicableCanada
Ibrancecapsule125 mg/1oralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
Ibrancecapsule125 mgoralPfizer Canada Inc2016-04-19Not applicableCanada
Ibrancecapsule125 mg/1oralU.S. Pharmaceuticals2015-02-03Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Palbociclib Isethionate
ThumbNot applicableDBSALT001110
Categories
UNIIG9ZF61LE7G
CAS number571190-30-2
WeightAverage: 447.5328
Monoisotopic: 447.238273207
Chemical FormulaC24H29N7O2
InChI KeyAHJRHEGDXFFMBM-UHFFFAOYSA-N
InChI
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
IUPAC Name
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one
SMILES
CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPyridinylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Pyridinylpiperazine
  • Pyridopyrimidine
  • Dialkylarylamine
  • Aryl alkyl ketone
  • Aryl ketone
  • Methylpyridine
  • Pyridinone
  • Aminopyridine
  • Imidolactam
  • Pyrimidine
  • Pyridine
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Lactam
  • Ketone
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
PharmacodynamicsTreatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb) phosphorylation resulting in reduced E2F expression and signaling and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens leads to increased cell senescence, which was sustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drug alone.
Mechanism of actionPalbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein.
Related Articles
AbsorptionThe mean Cmax of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration. The mean absolute bioavailability after an oral 125 mg dose is 46%.
Volume of distribution

The mean apparent distribution of palbociclib is 2583 L, suggesting that palbociclib penetrates extensively into peripheral tissues.

Protein bindingBinding of palbociclib to human plasma proteins in vitro is approximately 85%.
Metabolism

The primary metabolic pathways for palbociclib involve oxidation and sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib is the major circulating drug-derived entity in plasma (23%). The major circulating metabolite was found to be a glucuronide conjugate of palbociclib, although it only represented 1.5% of the administered dose in the excreta.

Route of eliminationPalbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.
Half lifeThe mean plasma elimination half-life is 29 hours.
Clearance

63.1 L/hr

ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral125 mg/1
Capsuleoral125 mg
Capsuleoral75 mg/1
Capsuleoral75 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6936612 No2003-01-222023-01-22Us
US7208489 No2003-01-162023-01-16Us
US7456168 No2003-01-162023-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa7.4 (the secondary piperazine nitrogen) and 3.9 (the pyridine nitrogen)FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP2.12ALOGPS
logP2.77ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)11.34ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.47 m3·mol-1ChemAxon
Polarizability49.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Dhillon S: Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9. [PubMed:25792301 ]
  2. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]
  3. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. [PubMed:23898052 ]
  4. Authors unspecified: Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2. [PubMed:26036642 ]
  5. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. [PubMed:26030518 ]
  6. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. [PubMed:25524798 ]
  7. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. [PubMed:25501126 ]
External Links
ATC CodesL01XE33
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (481 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Palbociclib.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Palbociclib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Palbociclib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Palbociclib.
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Palbociclib.
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Palbociclib.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Palbociclib.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Palbociclib.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Palbociclib.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Palbociclib.
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Palbociclib.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Palbociclib.
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Palbociclib.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Palbociclib.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Palbociclib.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Palbociclib.
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Palbociclib.
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Palbociclib.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Palbociclib.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Palbociclib.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Palbociclib.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Palbociclib.
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Palbociclib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Palbociclib.
AprepitantThe serum concentration of Palbociclib can be increased when it is combined with Aprepitant.
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Palbociclib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Palbociclib.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Palbociclib.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Palbociclib.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Palbociclib.
AtomoxetineThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Palbociclib.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Palbociclib.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Palbociclib.
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Palbociclib.
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Palbociclib.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Palbociclib.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Palbociclib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Palbociclib.
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Palbociclib.
BexaroteneThe serum concentration of Palbociclib can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Palbociclib.
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Palbociclib.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Palbociclib.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Palbociclib.
BortezomibThe metabolism of Palbociclib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Palbociclib.
BosentanThe serum concentration of Palbociclib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Palbociclib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Palbociclib.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Palbociclib.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Palbociclib.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Palbociclib.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Palbociclib.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Palbociclib.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Palbociclib.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Palbociclib.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Palbociclib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Palbociclib.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Palbociclib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Palbociclib.
CarbamazepineThe serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Palbociclib.
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Palbociclib.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Palbociclib.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Palbociclib.
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Palbociclib.
CeritinibThe serum concentration of Palbociclib can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Palbociclib.
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Palbociclib.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Palbociclib.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Palbociclib.
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Palbociclib.
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Palbociclib.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Palbociclib.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Palbociclib.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Palbociclib.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Palbociclib.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Palbociclib.
ClemastineThe metabolism of Palbociclib can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Palbociclib.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Palbociclib.
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Palbociclib.
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Palbociclib.
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Palbociclib.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Palbociclib.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Palbociclib.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Palbociclib.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Palbociclib.
ClotrimazoleThe metabolism of Palbociclib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Palbociclib is combined with Clozapine.
CobicistatThe serum concentration of Palbociclib can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Palbociclib.
CodeineThe serum concentration of Codeine can be increased when it is combined with Palbociclib.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Palbociclib.
ConivaptanThe serum concentration of Palbociclib can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Palbociclib.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Palbociclib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Palbociclib.
CrizotinibThe metabolism of Palbociclib can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Palbociclib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.
CyclosporineThe metabolism of Palbociclib can be decreased when combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Palbociclib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Palbociclib.
DabrafenibThe serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Palbociclib.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Palbociclib.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Palbociclib.
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Palbociclib.
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Palbociclib.
DasatinibThe serum concentration of Palbociclib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Palbociclib.
DeferasiroxThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Palbociclib.
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Palbociclib.
DelavirdineThe metabolism of Palbociclib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Palbociclib.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Palbociclib.
DexamethasoneThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Palbociclib.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Palbociclib.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Palbociclib.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Palbociclib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Palbociclib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Palbociclib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palbociclib.
DigoxinDigoxin may decrease the cardiotoxic activities of Palbociclib.
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib.
DihydroergotamineThe metabolism of Palbociclib can be decreased when combined with Dihydroergotamine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Palbociclib.
DiltiazemThe metabolism of Palbociclib can be decreased when combined with Diltiazem.
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Palbociclib.
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Palbociclib.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Palbociclib.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Palbociclib.
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Palbociclib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Palbociclib.
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Palbociclib.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Palbociclib.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Palbociclib.
DoxycyclineThe metabolism of Palbociclib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Palbociclib.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Palbociclib.
DronedaroneThe metabolism of Palbociclib can be decreased when combined with Dronedarone.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Palbociclib.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Palbociclib.
EfavirenzThe serum concentration of Palbociclib can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Palbociclib.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Palbociclib.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Palbociclib.
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Palbociclib.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Palbociclib.
EnzalutamideThe serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Palbociclib.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Palbociclib.
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Palbociclib.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Palbociclib.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Palbociclib.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Palbociclib.
ErythromycinThe metabolism of Palbociclib can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.
Eslicarbazepine acetateThe serum concentration of Palbociclib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Palbociclib.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Palbociclib.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Palbociclib.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Palbociclib.
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Palbociclib.
EstroneThe serum concentration of Estrone can be increased when it is combined with Palbociclib.
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Palbociclib.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Palbociclib.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Palbociclib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palbociclib.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Palbociclib.
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Palbociclib.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Palbociclib.
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Palbociclib.
EtravirineThe serum concentration of Palbociclib can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Palbociclib.
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Palbociclib.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Palbociclib.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Palbociclib.
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Palbociclib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.
FluconazoleThe metabolism of Palbociclib can be decreased when combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Palbociclib.
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Palbociclib.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Palbociclib.
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Palbociclib.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Palbociclib.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Palbociclib.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Palbociclib.
FluvoxamineThe metabolism of Palbociclib can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Palbociclib.
FosamprenavirThe metabolism of Palbociclib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Palbociclib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Palbociclib.
Fusidic AcidThe serum concentration of Palbociclib can be increased when it is combined with Fusidic Acid.
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Palbociclib.
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Palbociclib.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Palbociclib.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Palbociclib.
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Palbociclib.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Palbociclib.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Palbociclib.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
HalothaneThe serum concentration of Halothane can be increased when it is combined with Palbociclib.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Palbociclib.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Palbociclib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Palbociclib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Palbociclib.
IdelalisibThe serum concentration of Palbociclib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Palbociclib.
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Palbociclib.
ImatinibThe metabolism of Palbociclib can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Palbociclib.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Palbociclib.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Palbociclib.
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Palbociclib.
IsavuconazoniumThe metabolism of Palbociclib can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Palbociclib.
IsradipineThe metabolism of Palbociclib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Palbociclib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Palbociclib.
IvacaftorThe serum concentration of Palbociclib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Palbociclib.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Palbociclib.
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Palbociclib.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Palbociclib.
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Palbociclib.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Palbociclib.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Palbociclib.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Palbociclib.
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Palbociclib.
LeflunomideThe risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Palbociclib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Palbociclib.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Palbociclib.
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Palbociclib.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Palbociclib.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib.
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Palbociclib.
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Palbociclib.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Palbociclib.
LisurideThe serum concentration of Lisuride can be increased when it is combined with Palbociclib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Palbociclib.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Palbociclib.
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Palbociclib.
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Palbociclib.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Palbociclib.
LosartanThe serum concentration of Losartan can be increased when it is combined with Palbociclib.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Palbociclib.
LovastatinThe metabolism of Palbociclib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Palbociclib can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Palbociclib.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Palbociclib.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Palbociclib.
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Palbociclib.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Palbociclib.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Palbociclib.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Palbociclib.
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Palbociclib.
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Palbociclib.
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Palbociclib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Palbociclib.
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Palbociclib.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Palbociclib.
MianserinThe serum concentration of Mianserin can be increased when it is combined with Palbociclib.
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Palbociclib.
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Palbociclib.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Palbociclib.
MifepristoneThe metabolism of Palbociclib can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.
MitotaneThe serum concentration of Palbociclib can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Palbociclib.
ModafinilThe serum concentration of Palbociclib can be decreased when it is combined with Modafinil.
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Palbociclib.
MorphineThe serum concentration of Morphine can be increased when it is combined with Palbociclib.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.
NafcillinThe serum concentration of Palbociclib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Palbociclib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Palbociclib.
NatalizumabThe risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Palbociclib.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Palbociclib.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Palbociclib.
NetupitantThe serum concentration of Palbociclib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Palbociclib.
NevirapineThe serum concentration of Palbociclib can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Palbociclib.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.
NilotinibThe metabolism of Palbociclib can be decreased when combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Palbociclib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Palbociclib.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Palbociclib.
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Palbociclib.
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Palbociclib.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Palbociclib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Palbociclib.
OlaparibThe metabolism of Palbociclib can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Palbociclib.
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Palbociclib.
OsimertinibThe serum concentration of Palbociclib can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Palbociclib.
OuabainOuabain may decrease the cardiotoxic activities of Palbociclib.
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Palbociclib.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Palbociclib.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Palbociclib.
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Palbociclib.
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Palbociclib.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Palbociclib.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Palbociclib.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Palbociclib.
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Palbociclib.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Palbociclib.
PergolideThe serum concentration of Pergolide can be increased when it is combined with Palbociclib.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Palbociclib.
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Palbociclib.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Palbociclib.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Palbociclib.
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Palbociclib.
PhenobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Palbociclib.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Palbociclib.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Palbociclib.
PhenytoinThe serum concentration of Palbociclib can be decreased when it is combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Palbociclib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib.
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Palbociclib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Palbociclib.
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Palbociclib.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Palbociclib.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Palbociclib.
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Palbociclib.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Palbociclib.
PosaconazoleThe serum concentration of Posaconazole can be increased when it is combined with Palbociclib.
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Palbociclib.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Palbociclib.
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Palbociclib.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Palbociclib.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Palbociclib.
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Palbociclib.
PrimidoneThe serum concentration of Palbociclib can be decreased when it is combined with Primidone.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Palbociclib.
PromazineThe serum concentration of Promazine can be increased when it is combined with Palbociclib.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.
PropofolThe serum concentration of Propofol can be increased when it is combined with Palbociclib.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Palbociclib.
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Palbociclib.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Palbociclib.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Palbociclib.
QuinineThe serum concentration of Quinine can be increased when it is combined with Palbociclib.
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Palbociclib.
Rabies vaccineThe risk or severity of adverse effects can be increased when Palbociclib is combined with Rabies vaccine.
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Palbociclib.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Palbociclib.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Palbociclib.
RanolazineThe metabolism of Palbociclib can be decreased when combined with Ranolazine.
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Palbociclib.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Palbociclib.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Palbociclib.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Palbociclib.
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Palbociclib.
RifabutinThe serum concentration of Palbociclib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Palbociclib.
RifampicinThe serum concentration of Palbociclib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Palbociclib can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Palbociclib.
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Palbociclib.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Palbociclib.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Palbociclib.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Palbociclib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Palbociclib.
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Palbociclib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Palbociclib.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Palbociclib.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Palbociclib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Palbociclib.
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Palbociclib.
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Palbociclib.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Palbociclib.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Palbociclib.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Palbociclib.
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Palbociclib.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Palbociclib.
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Palbociclib.
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Palbociclib.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Palbociclib.
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Palbociclib.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Palbociclib.
SildenafilThe metabolism of Palbociclib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.
SiltuximabThe serum concentration of Palbociclib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Palbociclib.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Palbociclib.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Palbociclib.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Palbociclib.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Palbociclib.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Palbociclib.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Palbociclib.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Palbociclib.
St. John's WortThe serum concentration of Palbociclib can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Palbociclib can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Palbociclib.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Palbociclib.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Palbociclib.
SulfisoxazoleThe metabolism of Palbociclib can be decreased when combined with Sulfisoxazole.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Palbociclib.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Palbociclib.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Palbociclib.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Palbociclib.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Palbociclib.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Palbociclib.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Palbociclib.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Palbociclib.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Palbociclib.
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Palbociclib.
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Palbociclib.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Palbociclib.
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Palbociclib.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Palbociclib.
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Palbociclib.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Palbociclib.
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Palbociclib.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Palbociclib.
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Palbociclib.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Palbociclib.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Palbociclib.
TiclopidineThe metabolism of Palbociclib can be decreased when combined with Ticlopidine.
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Palbociclib.
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Palbociclib.
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Palbociclib.
TocilizumabThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.
TofacitinibPalbociclib may increase the immunosuppressive activities of Tofacitinib.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Palbociclib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Palbociclib.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Palbociclib.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Palbociclib.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Palbociclib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Palbociclib.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Palbociclib.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Palbociclib.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Palbociclib.
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Palbociclib.
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Palbociclib.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Palbociclib.
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Palbociclib.
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Palbociclib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Palbociclib.
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Palbociclib.
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Palbociclib.
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Palbociclib.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Palbociclib.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Palbociclib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Palbociclib.
VenlafaxineThe metabolism of Palbociclib can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.
VerapamilThe metabolism of Palbociclib can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Palbociclib.
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Palbociclib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Palbociclib.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Palbociclib.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Palbociclib.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Palbociclib.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Palbociclib.
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Palbociclib.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Palbociclib.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Palbociclib.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Palbociclib.
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Palbociclib.
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Palbociclib.
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Palbociclib.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Palbociclib.
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Palbociclib.
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.
ZiprasidoneThe metabolism of Palbociclib can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Palbociclib.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Palbociclib.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Cyclin-dependent protein serine/threonine kinase regulator activity
Specific Function:
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progres...
Gene Name:
CDK4
Uniprot ID:
P11802
Molecular Weight:
33729.55 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Cyclin-dependent protein serine/threonine kinase activity
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation...
Gene Name:
CDK6
Uniprot ID:
Q00534
Molecular Weight:
36938.025 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
2. Sulfotransferase 2A1
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
Comments
comments powered by Disqus
Drug created on May 14, 2015 14:03 / Updated on October 01, 2016 02:25